Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy — LOCAL  

Lung Neoplasms Clinical Trial

Official title: Local Consolidative Therapy (LCT) in Patients With Advanced Stage Non-small Cell Lung Cancer Who do Not Progress After Front Line Systemic Therapy

Status Recruiting

Clinical Trial Summary

This is a prospective single arme real-world study clinical study, which aims to investigate the overall benefit and safety of consolidative therapy in advanced NSCLC (stage III/IV) patients , who do not progress after front line systemic therapy (chemotherapy, target therapy or immunological checkpoint inhibitors).

Clinical Trial Description

It is required that pathological diagnosis and genetic profile including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) be established prior to enrollment. Standard front line systemic should be given according to clinical practice. Molecular targeting drugs for patients with driving mutations should be acquired legally. Patients without driving mutations should undergo standard first line chemotherapy and or immunological checkpoint inhibitors. One cycle is three weeks and response evaluation is done every two cycles. CR, PR and SD should be confirmed after four cycles of therapy.

Patients, who achieve non-PD after four cycles of treatment, with distant metastasis involving no more than five total metastatic lesions, will be screened and enrolled. ;

Related Conditions & MeSH terms

• Lung Neoplasms

• NCT number: NCT03046316
• Study type: Interventional
• Source: Guangdong Association of Clinical Trials
• Contact: ZHEN WANG, PhD,MD
• Phone: +8683827812
• Email: hunterol@163.com
• Status: Recruiting
• Phase: N/A
• Start date: June 1, 2020
• Completion date: July 1, 2026